By SaiyanMed Research Team · Updated 5 November 2026 · For in-vitro research use only
RESEARCH USE ONLY — PROFESSIONAL LABORATORY USE. This article is for qualified laboratory personnel carrying out in-vitro assays or institutionally approved laboratory animal studies. It is not a home-use, personal-use, human-use, or veterinary-use guide. The information below must not be used as an administration, formulation, reconstitution, or dosing plan. Survodutide (BI 456906) is an investigational compound. Its safety and efficacy have not been approved for marketing by the FDA or other regulators for any indication. Clinical trial results are summarized here as published research / company IR data, not as medical advice. SaiyanMed does not list a survodutide product SKU on this page (catalog check 2026-11-05).
Quick answer
Survodutide (development code BI 456906) is an investigational long-acting dual agonist of the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). It is studied as a once-weekly subcutaneous investigational product. The peptide was licensed from Zealand Pharma to Boehringer Ingelheim, with Boehringer solely responsible for global development and commercialization [BI GlobeNewswire 2026-10-01; Zealand pipeline].
Public Phase 3 work is organized mainly under the SYNCHRONIZE obesity / overweight umbrella (including SYNCHRONIZE-1 without type 2 diabetes and SYNCHRONIZE-2 with type 2 diabetes) and the LIVERAGE program for metabolic dysfunction–associated steatohepatitis (MASH) with fibrosis [NCT06066515; NCT06066528; NCT06632444]. On 1 October 2026, Boehringer presented SYNCHRONIZE-2 primary data at EASD and reported simultaneous NEJM publication (DOI 10.1056/NEJMoa2607219) [BI 2026-10-01].
Survodutide is not the same molecule as:
| Peer (research context) | Public MoA headline | Why it is different |
|---|---|---|
| Retatrutide | Unimolecular GIP / GLP-1 / glucagon triple agonist | Adds GIP as a third headline pathway |
| Tirzepatide | Dual GIP / GLP-1 | No glucagon-receptor headline |
| Semaglutide | Mono GLP-1 | No GCGR agonism as public design |
| Zenagamtide | Unimolecular GLP-1 + amylin | Amylin pathway, not glucagon dual |
| Pemvidutide (peer class) | Another GLP-1 / glucagon dual peptide (Altimmune) | Different sponsor / program — do not conflate INNs |
Dual GCGR / GLP-1R pharmacology
What “glucagon/GLP-1 dual agonist” means in sponsor framing
Boehringer and Zealand describe survodutide as activating both the glucagon and GLP-1 receptors — pathways involved in metabolic regulation of energy intake, glycemic control, and hepatic lipid biology in research narratives [BI 2026-10-01; Zealand pipeline]. Zealand’s public pipeline language adds that the molecule was designed with strong bias toward GLP-1 receptors, intending to retain GLP-1-linked weight and glycemic themes while leveraging direct glucagon effects in the liver [Zealand pipeline].
| Approach | Example | Public receptor headline |
|---|---|---|
| Mono GLP-1 RA | Semaglutide | GLP-1R |
| Dual GIP/GLP-1 | Tirzepatide | GIPR + GLP-1R |
| Dual glucagon/GLP-1 | Survodutide | GCGR + GLP-1R |
| Triple GIP/GLP-1/glucagon | Retatrutide | GIPR + GLP-1R + GCGR |
| Dual GLP-1/amylin (unimolecular) | Zenagamtide | GLP-1R + amylin receptors |
Hedges that belong in any careful research summary
- In-vitro potency rankings are assay-specific (cell background, albumin, readout). This hub does not invent EC50 tables.
- Clinical % weight / HbA1c / liver-fat figures are trial-reported outcomes, not a reconstitution recipe or a ranking of “which vial to buy for patients.”
- Glucagon biology traditionally raises glucose in textbooks; sponsor dual-agonism narratives discuss balanced GCGR/GLP-1R engagement and hepatic fat themes — that is mechanistic pipeline language, not a personal-use rationale [BI 2026-10-01].
- Cross-trial % weight loss is not a clinical ranking versus retatrutide, tirzepatide, or zenagamtide.
Zealand → Boehringer licensing context
Survodutide originated in Zealand Pharma’s glucagon/GLP-1 dual-agonist research lineage and is licensed to Boehringer Ingelheim. Public partnering language states that Boehringer is solely responsible for development and commercialization globally, while Zealand remains eligible for milestones and royalties under the partnership economics described on Zealand’s site [Zealand partnering; Zealand pipeline; BI 2026-10-01].
Related Zealand DNA (different molecule): SaiyanMed’s petrelintide hub covers a Zealand-origin amylin analogue (ZP8396) co-developed with Roche — not survodutide. Shared company heritage ≠ shared pharmacology or trial programs.
SYNCHRONIZE Phase 3 program map
Milligram figures below are trial-reported dose labels from registries and sponsor press. They are not laboratory reconstitution or personal titration instructions.
| Trial | NCT | Population (high-level) | Status (CT.gov fetch 2026-11-05) | Notes |
|---|---|---|---|---|
| SYNCHRONIZE-1 | NCT06066515 | Overweight/obesity without T2D | COMPLETED (n=726 actual on CT.gov; NEJM abstract cites 725) | Obesity Ph3; NEJM DOI 10.1056/NEJMoa2600751 |
| SYNCHRONIZE-2 | NCT06066528 | Overweight/obesity with T2D | COMPLETED (n=755 actual) | EASD + NEJM 2026-10-01; DOI 10.1056/NEJMoa2607219 |
| SYNCHRONIZE-MASLD | NCT06309992 | Obesity/overweight + confirmed/presumed MASH | Listed in BI program narrative | Cite registry when expanding |
| SYNCHRONIZE-CVOT | NCT06077864 | Overweight/obesity + CVD / CKD / CV risk factors | CV outcomes | BI (Oct 2026) expected results “later this year” — treat as pending |
| SYNCHRONIZE-JP / -CN | NCT06176365 / NCT06214741 | Japan / China regional obesity programs | Regional Ph3 | High-level map only |
| SYNCHRONIZE-T2D | NCT07754461 | Adults with T2D (glycemic-control focus) | Additional Ph3 listed by BI | Not a SYNCHRONIZE-2 duplicate |
Common SYNCHRONIZE-1/2 design themes (registry): once-weekly SC 3.6 mg or 6.0 mg survodutide vs placebo; ~76 weeks; dual co-primary themes of % body-weight change and ≥5% weight reduction [NCT06066515; NCT06066528; BI 2026-10-01].
SYNCHRONIZE-2 obesity + T2D readout
Every figure below is a trial-reported outcome under the sponsor’s stated estimands. None of it is a dosing schedule, eligibility recommendation, or product claim for research vials.
Design snapshot
From ClinicalTrials.gov and Boehringer’s 1 Oct 2026 release [NCT06066528; BI 2026-10-01]:
| Field | Public value |
|---|---|
| Official framing | Phase 3, randomised, double-blind, parallel-group, 76-week efficacy/safety of SC BI 456906 vs placebo in overweight/obesity with T2D |
| Enrollment | 755 actual |
| Arms | Survodutide 3.6 mg, 6.0 mg, or placebo (weekly SC) |
| Co-primary endpoints | % change in body weight to Week 76; achievement of ≥5% weight reduction |
| Status | COMPLETED (primary completion 2025-12-12; completion 2026-04-01 on CT.gov) |
| Peer-reviewed pointer | Wharton S, et al. N Engl J Med 2026; DOI 10.1056/NEJMoa2607219 (cited in BI release; full text not fetched for this draft) |
Efficacy headline (BI press; efficacy estimand)
Boehringer reports that SYNCHRONIZE-2 met its co-primary endpoints under both the treatment-regimen and efficacy estimands [BI 2026-10-01]:
| Endpoint (76 weeks; efficacy estimand as stated) | Survodutide (up to…) | Placebo |
|---|---|---|
| Mean body-weight % change | −13.1% | −3.1% (p<0.0001; BI notes p-values for efficacy estimand are nominal) |
| ≥5% weight reduction | 79.3% | 32.7% (p<0.0001) |
| HbA1c change (baseline 7.4%) | −1.21% | −0.03% (p<0.0001) |
| Waist circumference change | −11.1 cm | −3.5 cm (p<0.0001) |
| Reversion to normoglycemia (HbA1c <5.7%) | up to 29.5% | 4.0% |
Sponsor footnotes on estimands [BI 2026-10-01]:
- Treatment-regimen estimand: estimated effect regardless of adherence, discontinuation, or initiation of other therapies.
- Efficacy estimand: estimated effect assuming participants remained on treatment for the entire study duration.
Additional sponsor language: improvements in fasting glucose and favorable changes in insulin resistance (HOMA-IR) and insulin secretion (HOMA-β) vs placebo [BI 2026-10-01]. Graded tables by exact dose arm (3.6 vs 6.0) for every secondary were not fully reproduced in the open press text used here — prefer the NEJM article for arm-level detail when accessible.
Tolerability (as reported)
Most common adverse events were gastrointestinal (nausea, vomiting, diarrhea, constipation), mostly mild to moderate — described as expected for GLP-1–based therapies and consistent with prior survodutide trials [BI 2026-10-01]. Treatment discontinuation due to GI AEs: 18% survodutide vs 1.2% placebo; discontinuations usually during dose escalation, with limited protocol flexibility noted by the sponsor [BI 2026-10-01].
Compliance note: Escalation / titration language in trial protocols is not a laboratory or personal-use recipe.
Gap flag: Full NEJM SYNCHRONIZE-2 HTML was Cloudflare-blocked during this draft — numeric claims above follow the BI press that cites the DOI. Reconcile arm-level tables against the journal when unblocked.
Body composition / liver-fat research angles (as published)
Alongside SYNCHRONIZE-2, Boehringer reported additional analyses from a SYNCHRONIZE-1 body-composition substudy (obesity without T2D; n=75) presented at EASD 2026 [BI 2026-10-01]:
- MRI-based assessments described preferential reductions in metabolically active visceral and liver fat.
- A muscle-specific analysis stated that muscle accounted for no more than 10% of total tissue lost (sponsor framing; builds on previously reported lean-mass findings).
- Sponsor interpretation: reductions in visceral and liver fat appeared largely independent of the degree of weight reduction, suggesting benefits that may extend beyond weight loss alone — treat as hypothesis-generating congress/press language, not as a completed regulatory label claim.
SYNCHRONIZE-1 main obesity readout (NEJM abstract — treatment-regimen)
For the primary obesity-without-diabetes Phase 3 paper [NEJM abstract DOI 10.1056/NEJMoa2600751; NCT06066515]:
| Field | Public value (abstract) |
|---|---|
| Participants | 725 (241 / 242 / 242 to 3.6 mg / 6.0 mg / placebo) — CT.gov lists 726 actual; use abstract for published analysis set |
| Baseline | Mean age 47.1 y; BMI 37.9; weight 108.8 kg; 40.6% men |
| Primary analysis | Treatment-regimen estimand (incorporates early discontinuation, prohibited obesity meds, prolonged escalation) |
| Mean weight % change @ wk 76 | −12.2% (3.6 mg), −13.0% (6.0 mg), −5.4% placebo |
| ≥5% weight reduction | 72.6%, 71.9%, 46.3% (P<0.001 vs placebo) |
| GI AEs | 80.9% (3.6), 89.7% (6.0), 47.9% placebo (typically mild–moderate) |
Gap flag: Efficacy-estimand % for SYNCHRONIZE-1 (sometimes quoted in secondary wires as higher than treatment-regimen) was not copied from Reuters/secondary into this hub’s primary table — prefer NEJM full text / BI primary for efficacy-estimand numbers before promoting them.
MASH LIVERAGE program
Survodutide’s differentiation story in the obesity incretin field often includes a MASH / fibrosis development path — not only weight endpoints.
| Program | NCT | Population (high-level) | Status / size (public) |
|---|---|---|---|
| LIVERAGE | NCT06632444 | Non-cirrhotic MASH / NASH with fibrosis stages F2–F3 | RECRUITING; ~1,800 estimated |
| LIVERAGE-Cirrhosis | NCT06632457 | Compensated MASH cirrhosis (F4) | ~1,590 planned per BI narrative |
LIVERAGE Part 1 primary themes (registry): resolution of MASH without worsening of fibrosis; ≥1-point fibrosis improvement without MASH worsening at Week 52. Part 2 follows longer-term clinical outcome composites [NCT06632444].
Regulatory designations (as claimed by sponsors — not approvals)
Boehringer / Zealand materials state that for non-cirrhotic MASH with moderate/advanced fibrosis, survodutide has received [BI 2026-10-01; Zealand pipeline]:
- U.S. FDA Fast Track (May 2021) and Breakthrough Therapy (September 2024)
- EMA PRIME scheme acceptance (November 2023)
- China’s NMPA Center for Drug Evaluation Breakthrough Therapy (June 2024)
- Taiwan FDA Breakthrough Designation (September 2024)
Designation ≠ approval. Survodutide remains investigational for all indications discussed here.
vs retatrutide / zenagamtide / pemvidutide (class literacy)
Cross-trial % weight loss is not a clinical ranking. Populations, estimands, durations, and background therapies differ.
| Dimension | Survodutide | Retatrutide | Zenagamtide |
|---|---|---|---|
| Public MoA | Dual GCGR + GLP-1R | Triple GIP + GLP-1 + GCGR | Dual GLP-1 + amylin (unimolecular) |
| Sponsor path | BI (Zealand-origin license) | Eli Lilly | Novo Nordisk |
| Obesity Ph3 example | SYNCHRONIZE-1/2 | TRIUMPH | AMAZE |
| Extra differentiation angle | Dedicated MASH LIVERAGE Ph3 | Broad TRIUMPH / TRANSCEND cardiometabolic | Amylin + GLP-1 in one peptide |
| SaiyanMed SKU (this draft) | None | Soft-link product exists | Wait for COA / educational hub |
Pemvidutide (Altimmune) is another investigational GLP-1/glucagon dual peptide in obesity/MASH research — peer-class literacy only; do not treat as a synonym for survodutide.
For SaiyanMed class reading: What Is Retatrutide? · What Is Zenagamtide (Amycretin)? · optional Zealand-heritage amylin hub What Is Petrelintide?.
Research / analytical identity notes
Why a vial label is not clinical identity
“Survodutide,” “BI 456906,” or informal grey-market nicknames on a lyophilized powder do not prove equivalence to Boehringer’s clinical-trial drug product. Dual-agonist peptides can fail by wrong sequence/length, incomplete modification, isomer content, aggregation, residual solvents, or simple mislabeling. Cake appearance is not an analytical method.
Stock status on SaiyanMed
No survodutide catalog SKU is claimed. Educational hub only (site product/post sitemap check 2026-11-05: no matching product or post URL). Notify-if-stock for any future RUO listing requires supplier COA review and explicit go-ahead — do not assume inventory from this article.
Minimum COA packet (if a research lot is ever listed)
| Item | Why it matters |
|---|---|
| Lot-matched COA | Must match the vial lot — not a “representative” PDF |
| RP-HPLC / UPLC purity + chromatogram | Area-% under a stated method; inspect shoulders |
| Intact-mass LC-MS | Observed vs theoretical mass for the intact modified peptide |
| Peptide content / counterion / water | Separates peptide mass from salt and residual solvent |
| Traceability | Manufacture/test dates, method IDs, lab identity |
Handling themes (no recipes)
Lyophilized peptides are commonly stressed by moisture, heat, light, and repeated freeze–thaw after reconstitution. Follow the batch COA and your institution’s validated procedures. This article does not provide diluent volumes, concentrations, injection instructions, titration schedules, or study protocols.
Myth vs evidence
| Myth | Evidence-based correction |
|---|---|
| “Survodutide is just another GLP-1 like semaglutide.” | Public design is dual GCGR + GLP-1R [BI 2026-10-01]. |
| “Same as retatrutide.” | Retatrutide adds GIP as a third headline pathway [retatrutide hub]. |
| “Same as zenagamtide / amycretin.” | Zenagamtide is GLP-1 + amylin, not glucagon dual [zenagamtide hub]. |
| “Same as petrelintide because both are Zealand.” | Petrelintide is an amylin analogue; survodutide is a glucagon/GLP-1 dual agonist [petrelintide hub]. |
| “−13.1% is interchangeable with SYNCHRONIZE-1’s −13.0%.” | Different populations (with vs without T2D), estimands, and papers — do not merge. |
| “Breakthrough Therapy means it is approved for MASH.” | Designation accelerates development/review dialogue; not a marketing authorization. |
| “RUO vials are for personal weight loss or liver DIY.” | Explicitly out of scope. |
Glossary
- Survodutide / BI 456906: Investigational dual glucagon / GLP-1 receptor agonist peptide (BI development; Zealand-origin license).
- GCGR: Glucagon receptor.
- GLP-1R: Glucagon-like peptide-1 receptor.
- SYNCHRONIZE: Boehringer Phase 3 program family in overweight/obesity (± T2D, MASLD, CVOT, regional).
- LIVERAGE: Phase 3 MASH / fibrosis program family.
- MASH: Metabolic dysfunction–associated steatohepatitis (related historical term: NASH).
- Efficacy estimand: Effect under idealized on-treatment assumptions as defined by the sponsor.
- Treatment-regimen estimand: Effect incorporating non-adherence / prohibited therapies / escalation delays as defined by the sponsor.
- RUO: Research Use Only — not for human or veterinary administration.
- COA: Certificate of Analysis for a specific lot.
FAQ
What is survodutide?
Survodutide (BI 456906) is an investigational once-weekly dual glucagon/GLP-1 receptor agonist peptide licensed from Zealand Pharma to Boehringer Ingelheim and studied in Phase 3 SYNCHRONIZE (obesity) and LIVERAGE (MASH) programs [BI 2026-10-01; Zealand pipeline].
What did SYNCHRONIZE-2 show?
In adults with obesity/overweight and type 2 diabetes (n=755; 76 weeks), BI reported efficacy-estimand mean weight change up to −13.1% vs −3.1% placebo, ≥5% responders up to 79.3% vs 32.7%, and HbA1c change up to −1.21% from baseline 7.4% vs −0.03% placebo, with simultaneous NEJM publication (DOI 10.1056/NEJMoa2607219) [BI 2026-10-01; NCT06066528].
What did SYNCHRONIZE-1 show?
In adults with obesity without diabetes, the NEJM abstract reports treatment-regimen mean weight change at week 76 of −12.2% (3.6 mg) and −13.0% (6.0 mg) vs −5.4% placebo [NEJM DOI 10.1056/NEJMoa2600751; NCT06066515].
Is survodutide FDA-approved?
No. Sponsors state it is investigational; efficacy and safety have not been established for marketing [BI 2026-10-01].
How does it differ from retatrutide?
Retatrutide is a triple GIP/GLP-1/glucagon agonist. Survodutide’s public headline is dual glucagon/GLP-1 without GIP as a third target [retatrutide hub].
How does it differ from zenagamtide?
Zenagamtide is a unimolecular GLP-1/amylin agonist. Survodutide engages glucagon + GLP-1, not amylin as the second headline pathway [zenagamtide hub].
Why do people mention MASH with survodutide?
Boehringer is running Phase 3 LIVERAGE / LIVERAGE-Cirrhosis trials in MASH with fibrosis, and public materials cite FDA Breakthrough / Fast Track and EMA PRIME designations for MASH fibrosis settings — still investigational [NCT06632444; Zealand pipeline].
Does SaiyanMed sell survodutide?
No SKU is claimed on this page (catalog check 2026-11-05). This hub is research education only.
Can I use these trial percentages as a personal protocol?
No. Trial figures are published research / IR data under specific protocols. This page provides no dosing, reconstitution, or titration guidance.
Key takeaways
- Survodutide (BI 456906) = investigational dual GCGR/GLP-1R agonist; Zealand → Boehringer license; no SaiyanMed stock claim.
- SYNCHRONIZE-2 (obesity+T2D, n=755, 76 wk): efficacy-estimand weight up to −13.1% vs placebo −3.1%; HbA1c up to −1.21% from 7.4%; NEJM DOI 10.1056/NEJMoa2607219 [BI 2026-10-01].
- SYNCHRONIZE-1 (NEJM abstract): treatment-regimen −12.2% / −13.0% vs −5.4% placebo at 76 weeks without T2D [DOI 10.1056/NEJMoa2600751].
- Body-composition substudy (SYNCHRONIZE-1 n=75): sponsor MRI narrative of preferential visceral/liver fat loss; muscle ≤10% of tissue lost [BI 2026-10-01].
- LIVERAGE MASH Ph3 + regulatory designations ≠ approval [NCT06632444].
- Class literacy: cross-link retatrutide and zenagamtide; do not conflate with petrelintide.
Related reading & research inquiry
- What Is Retatrutide?
- What Is Zenagamtide (Amycretin)?
- What Is Petrelintide? (Zealand-heritage amylin analogue — different MoA)
- What Is CagriSema? (amylin + GLP-1 combination, not glucagon dual)
CTA (SKU-gated): This page does not invent a survodutide inventory listing. If your laboratory later needs a documented research reference material, that requires COA review and explicit catalog go-ahead — not implied by this educational hub.
Research Use Only disclaimer
Research Use Only. Content summarizes published molecular, clinical-development, and company IR information for laboratory professionals. It does not provide medical or veterinary advice, validated experimental protocols, dosing or reconstitution instructions, or authorization for in-vivo work. Animal research requires applicable institutional approvals. Survodutide remains an investigational candidate unless and until a regulator issues an approved label — and even then, approved product labels are not RUO protocols. This article is not a substitute for any approved medicine’s label and is not a use guide for research powders.
Sources & further reading
- Boehringer Ingelheim — SYNCHRONIZE-2 press (2026-10-01) — GlobeNewswire
- NEJM SYNCHRONIZE-2 DOI (full text not fetched) — 10.1056/NEJMoa2607219
- NEJM SYNCHRONIZE-1 — DOI 10.1056/NEJMoa2600751
- ClinicalTrials.gov NCT06066528 (SYNCHRONIZE-2)
- ClinicalTrials.gov NCT06066515 (SYNCHRONIZE-1)
- ClinicalTrials.gov NCT06077864 (SYNCHRONIZE-CVOT)
- ClinicalTrials.gov NCT06309992 (SYNCHRONIZE-MASLD)
- ClinicalTrials.gov NCT06632444 (LIVERAGE)
- ClinicalTrials.gov NCT06632457 (LIVERAGE-Cirrhosis)
- ClinicalTrials.gov NCT07754461 (SYNCHRONIZE-T2D)
- Zealand Pharma — survodutide pipeline · partnering
- SaiyanMed — retatrutide · zenagamtide · petrelintide · CagriSema